vs
Side-by-side financial comparison of Boston Scientific (BSX) and Danaher Corporation (DHR). Click either name above to swap in a different company.
Danaher Corporation is the larger business by last-quarter revenue ($6.0B vs $5.2B, roughly 1.1× Boston Scientific). Boston Scientific runs the higher net margin — 25.7% vs 17.3%, a 8.4% gap on every dollar of revenue. On growth, Boston Scientific posted the faster year-over-year revenue change (11.6% vs 3.7%). Over the past eight quarters, Boston Scientific's revenue compounded faster (12.4% CAGR vs 1.8%).
Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Danaher CorporationDHREarnings & Financial Report
Danaher Corporation is an American healthcare company headquartered in Washington, D.C.. It develops products used for advances in biotechnology, life sciences, and diagnostics. The company operates three divisions: biotechnology, which develops products for the development of therapeutics; life sciences, which develops products to identify causes of disease, new therapies, and to test and manufacture new drugs, vaccines and gene editing technologies; and diagnostics, which develops instruments,...
BSX vs DHR — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $5.2B | $6.0B |
| Net Profit | $1.3B | $1.0B |
| Gross Margin | 69.5% | 60.3% |
| Operating Margin | — | 22.6% |
| Net Margin | 25.7% | 17.3% |
| Revenue YoY | 11.6% | 3.7% |
| Net Profit YoY | 99.0% | 7.9% |
| EPS (diluted) | $0.90 | $1.45 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $5.2B | $6.0B | ||
| Q4 25 | $5.3B | $6.8B | ||
| Q3 25 | $5.1B | $6.1B | ||
| Q2 25 | $5.1B | $5.9B | ||
| Q1 25 | $4.7B | $5.7B | ||
| Q4 24 | $4.6B | $6.5B | ||
| Q3 24 | $4.2B | $5.8B | ||
| Q2 24 | $4.1B | $5.7B |
| Q1 26 | $1.3B | $1.0B | ||
| Q4 25 | $670.0M | $1.2B | ||
| Q3 25 | $755.0M | $908.0M | ||
| Q2 25 | $795.0M | $555.0M | ||
| Q1 25 | $672.0M | $954.0M | ||
| Q4 24 | $563.0M | $1.1B | ||
| Q3 24 | $468.0M | $818.0M | ||
| Q2 24 | $322.0M | $907.0M |
| Q1 26 | 69.5% | 60.3% | ||
| Q4 25 | 69.6% | 58.0% | ||
| Q3 25 | 69.9% | 58.2% | ||
| Q2 25 | 67.7% | 59.3% | ||
| Q1 25 | 68.8% | 61.2% | ||
| Q4 24 | 67.8% | 59.5% | ||
| Q3 24 | 68.8% | 58.7% | ||
| Q2 24 | 69.2% | 59.7% |
| Q1 26 | — | 22.6% | ||
| Q4 25 | 15.6% | 22.0% | ||
| Q3 25 | 20.7% | 19.1% | ||
| Q2 25 | 16.2% | 12.8% | ||
| Q1 25 | 19.8% | 22.2% | ||
| Q4 24 | 14.8% | 21.8% | ||
| Q3 24 | 17.4% | 16.5% | ||
| Q2 24 | 12.6% | 20.3% |
| Q1 26 | 25.7% | 17.3% | ||
| Q4 25 | 12.7% | 17.5% | ||
| Q3 25 | 14.9% | 15.0% | ||
| Q2 25 | 15.7% | 9.3% | ||
| Q1 25 | 14.4% | 16.6% | ||
| Q4 24 | 12.3% | 16.6% | ||
| Q3 24 | 11.1% | 14.1% | ||
| Q2 24 | 7.8% | 15.8% |
| Q1 26 | $0.90 | $1.45 | ||
| Q4 25 | $0.45 | $1.69 | ||
| Q3 25 | $0.51 | $1.27 | ||
| Q2 25 | $0.53 | $0.77 | ||
| Q1 25 | $0.45 | $1.32 | ||
| Q4 24 | $0.38 | $1.50 | ||
| Q3 24 | $0.32 | $1.12 | ||
| Q2 24 | $0.22 | $1.22 |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $1.3B |
| Free Cash FlowOCF − Capex | — | $1.1B |
| FCF MarginFCF / Revenue | — | 18.2% |
| Capex IntensityCapex / Revenue | — | 4.0% |
| Cash ConversionOCF / Net Profit | — | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | — | $5.3B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.3B | ||
| Q4 25 | $1.4B | $2.1B | ||
| Q3 25 | $1.3B | $1.7B | ||
| Q2 25 | $1.3B | $1.3B | ||
| Q1 25 | $541.0M | $1.3B | ||
| Q4 24 | $1.5B | $2.0B | ||
| Q3 24 | $1.0B | $1.5B | ||
| Q2 24 | $813.0M | $1.4B |
| Q1 26 | — | $1.1B | ||
| Q4 25 | $1.0B | $1.7B | ||
| Q3 25 | $1.2B | $1.4B | ||
| Q2 25 | $1.1B | $1.1B | ||
| Q1 25 | $354.0M | $1.1B | ||
| Q4 24 | $1.2B | $1.5B | ||
| Q3 24 | $823.0M | $1.2B | ||
| Q2 24 | $658.0M | $1.1B |
| Q1 26 | — | 18.2% | ||
| Q4 25 | 19.2% | 25.5% | ||
| Q3 25 | 22.9% | 22.6% | ||
| Q2 25 | 22.3% | 18.4% | ||
| Q1 25 | 7.6% | 18.4% | ||
| Q4 24 | 25.8% | 23.0% | ||
| Q3 24 | 19.6% | 21.0% | ||
| Q2 24 | 16.0% | 19.7% |
| Q1 26 | — | 4.0% | ||
| Q4 25 | 6.6% | 5.4% | ||
| Q3 25 | 3.6% | 4.8% | ||
| Q2 25 | 3.1% | 4.2% | ||
| Q1 25 | 4.0% | 4.3% | ||
| Q4 24 | 6.1% | 7.9% | ||
| Q3 24 | 4.3% | 5.1% | ||
| Q2 24 | 3.8% | 5.0% |
| Q1 26 | — | 1.28× | ||
| Q4 25 | 2.04× | 1.77× | ||
| Q3 25 | 1.78× | 1.83× | ||
| Q2 25 | 1.62× | 2.41× | ||
| Q1 25 | 0.81× | 1.36× | ||
| Q4 24 | 2.59× | 1.86× | ||
| Q3 24 | 2.14× | 1.85× | ||
| Q2 24 | 2.52× | 1.56× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BSX
| Cardiovascular | $3.1B | 59% |
| Endoscopy | $673.0M | 13% |
| Urology | $633.0M | 12% |
| Other | $386.0M | 7% |
| Neuromodulation | $271.0M | 5% |
| LACA | $155.0M | 3% |
DHR
Segment breakdown not available.
